Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

BACKGROUND: Hereditary angioedema (HAE) is a debilitating disorder resulting from C1-esterase inhibitor (C1-INH) deficiency. In the COMPACT phase 3 study the prophylactic use of a subcutaneous C1 inhibitor (C1-INH [SC], HAEGARDA(®), CSL Behring) twice weekly significantly reduced the frequency of ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, H. Henry, Zuraw, Bruce, Longhurst, Hilary J., Cicardi, Marco, Bork, Konrad, Baker, James, Lumry, William, Bernstein, Jonathan, Manning, Michael, Levy, Donald, Riedl, Marc A., Feuersenger, Henrike, Prusty, Subhransu, Pragst, Ingo, Machnig, Thomas, Craig, Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714075/
https://www.ncbi.nlm.nih.gov/pubmed/31485239
http://dx.doi.org/10.1186/s13223-019-0362-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714075/
https://www.ncbi.nlm.nih.gov/pubmed/31485239
http://dx.doi.org/10.1186/s13223-019-0362-1

Ejemplares similares